THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL

Bibliographic Details
Main Authors:	Madi, A, Wilson, R, Adams, R, Seymour, M, Meade, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T
Format:	Conference item
Published:	2010

Similar Items

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
by: Adams, R, et al.
Published: (2009)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
by: Adams, R, et al.
Published: (2010)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
by: Maughan, T, et al.
Published: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
by: Madi, A, et al.
Published: (2012)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
by: Adams, R, et al.
Published: (2009)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Adams, R, et al.
Published: (2011)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
by: Maughan, T, et al.
Published: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
by: Maughan, T, et al.
Published: (2010)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Maughan, T, et al.
Published: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
by: Adams, R, et al.
Published: (2009)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
by: Wasan, H, et al.
Published: (2011)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
by: Wood, G, et al.
Published: (2017)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
by: Adams, R, et al.
Published: (2008)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
by: Iveson, T, et al.
Published: (2018)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
by: Taieb, J, et al.
Published: (2012)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
by: West, H, et al.
Published: (2018)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
by: Maughan, T, et al.
Published: (2010)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
by: Madi, A, et al.
Published: (2018)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
by: Seymour, M, et al.
Published: (2007)

Oxaliplatin-Related Ocular Toxicity
by: Marina Mesquida, et al.
Published: (2010-11-01)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
by: Elena De Mattia, et al.
Published: (2022-10-01)

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis
by: Alessandro Parisi, et al.
Published: (2022-08-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
by: Seymour, M, et al.
Published: (2007)

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine‐induced toxicity in an Asian population
by: Masashi Kanai, et al.
Published: (2023-04-01)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
by: Angela Wu, et al.
Published: (2023-09-01)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
by: J. M. Short, et al.
Published: (2023-09-01)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
by: Michał Jurczyk, et al.
Published: (2021-09-01)

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study
by: Côme De Metz, et al.
Published: (2024-03-01)

<i>DPYD</i> Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
by: Theodore J. Wigle, et al.
Published: (2023-01-01)

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab
by: Madi, A, et al.
Published: (2017)

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
by: Elena De Mattia, et al.
Published: (2023-11-01)

The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens
by: Ali Tavakoli Pirzaman MD, et al.
Published: (2023-10-01)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
by: Laura Grumetti, et al.
Published: (2022-01-01)

Fluoropyrimidines affect de novo pyrimidine synthesis impairing biofilm formation in Escherichia coli
by: Srikanth Ravishankar, et al.
Published: (2024-06-01)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
by: Seymour, M, et al.
Published: (2011)

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
by: Wei Tian, et al.
Published: (2023-01-01)

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
by: Wei Tian, et al.
Published: (2023-01-01)

Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status
by: M. Yu. Fedyanin, et al.
Published: (2018-05-01)

The MRC spine stabilization trial
by: Wilson-MacDonald, J, et al.
Published: (2008)